Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0TN7S
|
||||
| Former ID |
DIB005839
|
||||
| Drug Name |
BAY-1075553
|
||||
| Indication | Prostate cancer [ICD9: 185; ICD10:C61] | Phase 1 | [1] | ||
| Company |
Bayer AG
|
||||
| Target and Pathway | |||||
| Target(s) | Glutamate carboxypeptidase II | Target Info | Modulator | [2] | |
| KEGG Pathway | Alanine, aspartate and glutamate metabolism | ||||
| Metabolic pathways | |||||
| Vitamin digestion and absorption | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| TNFalpha Signaling Pathway | |||||
| Reactome | Amino acid synthesis and interconversion (transamination) | ||||
| WikiPathways | One Carbon Metabolism | ||||
| References | |||||
| REF 1 | Phase I Study: BAY 1075553 PET/CT in Staging and Re - Staging of Prostate Cancer Patients - Comparison with 18F-Choline PET/CT. World Molecular Imaging Society. September 20, 2013 | ||||
| REF 2 | Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):89-101. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.